SCHEMBL23979459

SCHEMBL23979459

COC(=O)c1ccc(Cl)cc1CNC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.48
ATR Q13535 1/20 0.47
IDO1 P14902 2/20 0.46
GAA P10253 2/20 0.44
ALDH1A1 P00352 4/20 0.42
HPGD P15428 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.42
ALOX12 P18054 1/20 0.42
KDM4A O75164 1/20 0.41
KCNA5 P22460 1/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NR4A2 P43354 2/20 0.40
ANO1 Q5XXA6 1/20 0.40
TP53 P04637 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23979460 0.88 IDO1 (0.47) IDO1GAAALDH1A1HPGDKDM4E
SCHEMBL6921464 0.86 IDO1 (0.50) IDO1GAAALDH1A1HPGDKDM4E
SCHEMBL27988801 0.83 IDO1 (0.53) IDO1GAAALDH1A1HPGDKDM4E
SCHEMBL3734185 0.82 ANO1 (0.51) IDO1GAAALDH1A1HPGDKDM4E
SCHEMBL23997640 0.82 IDO1 (0.52) IDO1GAAALDH1A1HPGDKDM4E
SCHEMBL29793580 0.81 GAA (0.49) IDO1GAAALDH1A1HPGDKDM4E
SCHEMBL21987969 0.81 IDO1 (0.48) ABL1IDO1GAAALDH1A1HPGD
SCHEMBL4757294 0.81 GAA (0.49) IDO1GAAALDH1A1HPGDKDM4E
SCHEMBL6919952 0.81 IDO1 (0.51) IDO1GAAALDH1A1HPGDKDM4E
SCHEMBL2158784 0.81 KCNA5 (0.55) ATRGAAALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115667236-B 1, 5-Dihydro-2, 4-benzodiazepine-3-one derivative and application thereof 江苏恩华药业股份有限公司 2024-04-26 CN disclosed
CN-116444484-A Salts of 1, 5-dihydro-2, 4-benzodiazepine-3-one derivatives and uses thereof 江苏恩华药业股份有限公司 2023-07-18 CN disclosed
US-20230132621-A1 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) 2023-05-04 US disclosed
CN-115667236-A 1,5-dihydro-2,4-benzodiazepine-3-one derivative and use thereof 江苏恩华药业股份有限公司 2023-01-31 CN disclosed
WO-2021218863-A1 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF 江苏恩华药业股份有限公司 (CN) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132621-A1 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF HTR2C, HTR2A, HTR2B ABL1 4586/4885ATR 4805/4885IDO1 1690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.